Defining utility values for patients with tardive dyskinesia-Reference-Cited by-同舟云学术

Defining utility values for patients with tardive dyskinesia

Published:2022-01-21 Issue:3 Volume:38 Page:401-407
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Ayyagari Rajeev¹^ORCID,Goldschmidt Debbie²^ORCID,Zhou Mo¹,Ribalov Rinat³,Caroff Stanley N.⁴^ORCID,Leo Sam⁵

Affiliation:

1. Analysis Group, Inc, Boston, MA, USA

2. Analysis Group, Inc, New York, NY, USA

3. Teva Pharmaceuticals, Tel Aviv, Israel

4. Department of Psychiatry, Michael J. Crescenz VA Medical Center and the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

5. Teva Pharmaceuticals, Parsippany, NJ, USA

Funder

Teva Pharmaceutical Industries Ltd

Teva Pharmaceuticals

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.2022918

Reference22 articles.

1. Diagnostic and statistical manual of mental disorders (DSM-5®). Washington (DC): American Psychiatric Association; 2013 [cited 8 October 2021]. Available from: https://www.psychiatry.org/psychiatrists/practice/dsm.

2. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

3. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

4. The Role of Long Acting Antipsychotics in Bipolar Disorder

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications;Frontiers in Psychiatry;2023-06-02